Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK

B C Reeves; S P Harding; J Langham; R Grieve; K Tomlin; J Walker; C Guerriero; J Carpenter; W P Patton; K A Muldrew; T Peto; U Chakravarthy

doi:10.3310/hta16060

Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK

B C Reeves, S P Harding, J Langham, R Grieve, K Tomlin, J Walker, C Guerriero, J Carpenter, W P Patton, K A Muldrew, T Peto, U Chakravarthy

Bristol Medical School (THS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

13 Citations (Scopus)

Abstract

The verteporfin photodynamic therapy (VPDT) cohort study aimed to answer five questions: (a) is VPDT in the NHS provided as in randomised trials?; (b) is 'outcome' the same in the nhs as in randomised trials?; (c) is 'outcome' the same for patients ineligible for randomised trials?; (d) is VPDT safe when provided in the NHS?; and (e) how effective and cost-effective is VPDT?

Original language	English
Pages (from-to)	i-xii, 1-200
Journal	Health Technology Assessment
Volume	16
Issue number	6
DOIs	https://doi.org/10.3310/hta16060
Publication status	Published - 2012

Structured keywords

BTC (Bristol Trials Centre)

Keywords

Porphyrins
Randomized Controlled Trials as Topic
Humans
Aged
Macular Degeneration
Outcome Assessment (Health Care)
Great Britain
State Medicine
Registries
Retinal Neovascularization
Photosensitizing Agents
Aged, 80 and over
Cost-Benefit Analysis
Cohort Studies
Middle Aged
Female
Male

Access to Document

10.3310/hta16060

Handle.net

Persistent link

Cite this

@article{b78dc57507dc4f0c85460b0180c6ba3c,

title = "Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK",

abstract = "The verteporfin photodynamic therapy (VPDT) cohort study aimed to answer five questions: (a) is VPDT in the NHS provided as in randomised trials?; (b) is 'outcome' the same in the nhs as in randomised trials?; (c) is 'outcome' the same for patients ineligible for randomised trials?; (d) is VPDT safe when provided in the NHS?; and (e) how effective and cost-effective is VPDT?",

keywords = "Porphyrins, Randomized Controlled Trials as Topic, Humans, Aged, Macular Degeneration, Outcome Assessment (Health Care), Great Britain, State Medicine, Registries, Retinal Neovascularization, Photosensitizing Agents, Aged, 80 and over, Cost-Benefit Analysis, Cohort Studies, Middle Aged, Female, Male",

author = "Reeves, {B C} and Harding, {S P} and J Langham and R Grieve and K Tomlin and J Walker and C Guerriero and J Carpenter and Patton, {W P} and Muldrew, {K A} and T Peto and U Chakravarthy",

year = "2012",

doi = "10.3310/hta16060",

language = "English",

volume = "16",

pages = "i--xii, 1--200",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "NIHR Journals Library",

number = "6",

}

TY - JOUR

T1 - Verteporfin photodynamic therapy for neovascular age-related macular degeneration

T2 - cohort study for the UK

AU - Reeves, B C

AU - Harding, S P

AU - Langham, J

AU - Grieve, R

AU - Tomlin, K

AU - Walker, J

AU - Guerriero, C

AU - Carpenter, J

AU - Patton, W P

AU - Muldrew, K A

AU - Peto, T

AU - Chakravarthy, U

PY - 2012

Y1 - 2012

N2 - The verteporfin photodynamic therapy (VPDT) cohort study aimed to answer five questions: (a) is VPDT in the NHS provided as in randomised trials?; (b) is 'outcome' the same in the nhs as in randomised trials?; (c) is 'outcome' the same for patients ineligible for randomised trials?; (d) is VPDT safe when provided in the NHS?; and (e) how effective and cost-effective is VPDT?

AB - The verteporfin photodynamic therapy (VPDT) cohort study aimed to answer five questions: (a) is VPDT in the NHS provided as in randomised trials?; (b) is 'outcome' the same in the nhs as in randomised trials?; (c) is 'outcome' the same for patients ineligible for randomised trials?; (d) is VPDT safe when provided in the NHS?; and (e) how effective and cost-effective is VPDT?

KW - Porphyrins

KW - Randomized Controlled Trials as Topic

KW - Humans

KW - Aged

KW - Macular Degeneration

KW - Outcome Assessment (Health Care)

KW - Great Britain

KW - State Medicine

KW - Registries

KW - Retinal Neovascularization

KW - Photosensitizing Agents

KW - Aged, 80 and over

KW - Cost-Benefit Analysis

KW - Cohort Studies

KW - Middle Aged

KW - Female

KW - Male

U2 - 10.3310/hta16060

DO - 10.3310/hta16060

M3 - Article (Academic Journal)

C2 - 22348600

VL - 16

SP - i-xii, 1-200

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 6

ER -

Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK

Abstract

Structured keywords

Keywords

Access to Document

Handle.net

Fingerprint

Cite this